A phase Ib trial of the combination of the anti-angiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies

PURPOSE: This phase I trial evaluated sunitinib combined with radiation therapy (RT) for primary or metastatic central nervous system (CNS) malignancies. EXPERIMENTAL DESIGN: Eligible patients had CNS malignancies requiring a (minimum) two week course of RT. Sunitinib (37.5 mg) was administered dail...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wuthrick, Evan J., Kamrava, Mitchell, Curran, Walter J., Werner-Wasik, Maria, Camphausen, Kevin A., Hyslop, Terry, Axelrod, Rita, Andrews, David W., Glass, Jon, Machtay, Mitchell, Dicker, Adam P.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2011
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3170674/
https://ncbi.nlm.nih.gov/pubmed/21647871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26216
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares